A skin health specialist, which raised £4.5m when it listed on the London stock market last week, will use the funds to drive forward its probiotic technology for skin health applications.
SkinBioTherapeutics, a University of Manchester spin-out, will focus on developing and commercialising its SkinBiotix technology platform.
The funds raised will enable it to focus on its development portfolio of three programmes – in skin care (sensitive skin), anti-infection and eczema.
You might be interested
December 27, 2017
- Office 11A, Challenge House, 616 Mitcham Road, Croydon, CR0 3AA
- 020 3674 7958